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What’s already known about this topic?  
Previous population-based studies suggest that the prevalence of hidradenitis suppurativa (HS) may 
be as low as 0.05% but did not quantify undiagnosed cases. 
What does this study add? 
Analysis of 4.3 million research-standard records in the UK Clinical Practice Research Datalink 
demonstrates a HS prevalence of 0.77% using the most stringent disease definition (95% CI 0.76 to 
0.78%), one-third being undiagnosed cases, rising to 1.19% (95% CI 1.18 to 1.20%) if probable cases 
are included. 
 
Summary 
Background  
Epidemiology data regarding hidradenitis suppurativa (HS) are conflicting and prevalence estimates 
vary 80-fold, from 0.05% in a population-based study, to 4%.   
Objectives 
To assess the hypothesis that previous population-based studies under-estimated true HS 
prevalence by missing undiagnosed cases. 
Methods   
We performed a population-based observational and case-control study using the UK Clinical 
Practice Research Datalink (CPRD) linked to Hospital Episode Statistics data. Physician-diagnosed 
cases in CPRD were identified from specific Read codes. Algorithms identified unrecognised ‘proxy’ 
cases, with at least five Read code records for boils in flexural skin sites. Validation of proxy cases 
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was undertaken with General Practitioner questionnaires to confirm criteria-diagnosed cases. A 
case-control study assessed disease associations. 
Results 
On 30 June 2013, 23,353 physician-diagnosed HS cases were documented in 4,364,308 research-
standard records. 68,890 proxy cases were identified, reduced to 10,146 criteria-diagnosed cases 
after validation, extrapolated from 107 completed questionnaires (61% return rate). Overall point 
prevalence was 0.77% (95% CI 0.76% to 0.78%). An additional 18,417 cases had a history of 1-4 
flexural skin boils.  
In physician-diagnosed cases, ORs for current smoker and obesity (BMI>30) were 3.61 (95% CI 3.44 
to 3.79) and 3.29 (95% CI 3.14 to 3.45). HS was associated with type 2 diabetes, Crohn’s disease, 
hyperlipidaemia, acne and depression and not associated with ulcerative colitis or polycystic ovary 
syndrome. 
Conclusions  
Contrary to results of previous population-based studies, HS is relatively common, with a UK 
prevalence of 0.77%, one-third being unrecognised, criteria-diagnosed cases using the most 
stringent disease definition. If probable cases are included, HS prevalence rises to 1.19%.    
 
Introduction 
Hidradenitis suppurativa (HS), also known as acne inversa, is an inflammatory skin disease producing 
functional impairment similar in magnitude to cardiovascular disease, type 2 diabetes and renal 
failure, due to pain, purulent discharge and scarring.1,2 HS is defined clinically by characteristic 
lesions occurring chronically in flexural locations.3,4 Consensus disease definitions differ slightly in 
the chronicity element, ranging from a history of two to five boils in the axillae or groins.5,6  
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The prevalence of HS remains controversial, with estimates ranging from 0.05% from an analysis of 
patient insurance claims in the USA,7 to 4% when young adult women were examined in person.8 An 
accurate prevalence figure is required to quantify the unmet need regarding care of people with HS 
to assess disease burden and plan health care provision. In particular radical surgery or biological 
therapies are needed for severe disease which are costly and often require multi-disciplinary teams; 
for example, in the UK, the National Institute for Health and Care Excellence (NICE) recently 
approved adalimumab for moderate to severe HS.9  
One explanation for the 80-fold difference in prevalence estimates currently available is lack of 
recognition of HS, in the context that average diagnostic delay is seven years.10 The aim of our study 
was to provide the most accurate estimate to date of HS prevalence by quantifying physician-
diagnosed cases, as well as unrecognised HS cases meeting the most stringent consensus disease 
definition for HS. A primary care data source was chosen because the majority of HS care takes place 
within a primary care setting. Our second aim was to assess HS disease associations with the largest 
case-control study performed to date. Accurate epidemiological data is critical at a time when 
treatment for HS is dramatically changing and now includes biological therapies.      
 
Patients and methods 
Our manuscript was prepared in accordance with RECORD, Reporting of Studies Conducted using 
Observational Routinely-collected Data11 (for RECORD checklist see Appendix S1; Supporting 
Information). The Clinical Practice Research Datalink (CPRD) contains routinely recorded, 
pseudonymised data from participating primary care practices throughout the UK.12 Most diagnoses 
made in secondary care are transcribed into CPRD by primary care staff. At January 2015, it 
contained records from more than 15.6 million patients registered at 684 practices. Patients are 
labelled by CPRD as being of acceptable research quality if they have been permanently registered at 
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their general practice and have internally consistent records with regard to age, sex, registration, 
and event dates. Approximately 75% of contributing practices based in England (representing 60% of 
the entire data set) participate in a CPRD linkage scheme by which patient-level data are linked to 
the Hospital Episode Statistics (HES) for England. The NHS number, date of birth, sex and postal code 
of non-dissenting patients are conveyed from the practice to a trusted third party and matched with 
equivalent identifiers in the target data set. Only those linkages involving at least two exact matches, 
which must include an exact match on NHS number, are retained.  
The study population was selected from patients of acceptable research quality. Physician-diagnosed 
cases of HS were captured by two specific diagnostic Read codes, M25y100 (Hidradenitis) and 
M25y111 (Hidradenitis suppurativa), or, in HES data, by the ICD-10 code L73.2 (Hidradenitis 
suppurativa). To capture undiagnosed cases, CPRD Read code algorithms were created to identify 
patients attending primary care for multiple skin boil consultations (Table 1). An algorithm hierarchy 
was used with different degrees of stringency for each sub-algorithm, based on the HS disease 
definition (Fig. 1). Some primary care practitioners may not record every skin boil consultation, 
particularly if the patient also attends with other health issues. To capture these potential cases, 
treatment codes were used to identify patients receiving multiple short courses of skin-directed 
antibiotic therapy, such as flucloxacillin, in combination with skin boil Read codes and in the absence 
of any other indication for the antibiotic, such as eczema, cellulitis or skin ulcers. Prior to validation, 
these patients are referred to as ‘proxy cases.’ HES data were not used to identify proxy cases to 
avoid double-counting boils recorded in both data sources. 
Validation 
Validation of proxy cases was carried out by sending questionnaires to the primary care physicians of 
a subset of patients identified from the algorithms. The questionnaire (Table 2) requested 
confirmation of characteristic skin lesions in flexural locations on at least five separate occasions, in 
keeping with the most stringent consensus definition of the disease.6  
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A total of 176 questionnaires were sent, with the overall number being determined by our study 
budget in the context that CPRD charges a fee for each questionnaire issued. The number of 
questionnaires generated to validate each sub-algorithm was determined by the number of 
additional proxy cases identified through each, with a minimum of 10 questionnaires being issued 
for sub-algorithms that captured relatively few cases.  
Analysis 
Point prevalence on 30 June 2013 was calculated using physician-diagnosed cases and criteria-
diagnosed cases as the numerator and the 2013 mid-year population of live patients with research-
standard records in CPRD as the denominator. The number of criteria-diagnosed cases was 
calculated by multiplying the number of proxy cases identified by each sub-algorithm with the 
proportion of cases validated from the relevant set of GP questionnaires. 
Annual incidence rates for physician-diagnosed cases were calculated from 1988, when up-to-
research standard practices first contributed to CPRD, until 2013. We used the Brameld-Holman 
backcasting method, which implements an actuarial retrograde survival curve to derive correction 
factors for the over-ascertainment of first events for individuals with only a limited duration of CPRD 
data collection prior to the event.13 The Brameld-Holman method accounts for the prevalent pool 
effect without the need for a clearance period and avoids data being discarded.  
Case-control 
Cases and controls were matched in a 1:1 ratio based on age, gender and registration at the same 
primary care practice. The associations between HS and environmental factors and other medical 
conditions were estimated using conditional logistic regression techniques. Two separate association 
analyses were conducted for physician-diagnosed cases compared with matched controls and for 
proxy cases (including criteria-diagnosed HS cases and those proxy cases who did not meet the 
validation criteria) compared to a further set of matched controls. Univariable associations were 
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reported, as well as multivariable analyses that examined combinations of variables demonstrating 
association in the univariable analysis with a P-value <0.1. In a post-hoc analysis we also tested 
whether there was evidence that the association between Crohn’s disease and HS was altered by 
smoking status because smoking is known to be a risk factor for both conditions. 
IRB Approval 
Our study protocol (Appendix S2; see Supporting Information), 15_020R, was prospectively 
approved by the CPRD Independent Scientific Advisory Committee. No additional Institutional 
Review Board approval is required for CPRD studies. 
 
Results 
Point prevalence  
On 30 June 2013 there were 21,575 physician-diagnosed HS patients in the CPRD dataset and a 
further 1778 from the HES dataset, a total of 23,353 physician-diagnosed cases. Our Read and 
treatment code algorithms captured a further 68,890 proxy cases in CPRD; the breakdown for each 
sub-algorithm is shown in Table 3. Of the 176 GP validation questionnaires sent, 107 (61%) were 
fully completed and returned; completion rates for each sub-algorithm are again in Table 3.  
The proportions of questionnaires with ‘yes’ responses to the first three questions, satisfying the 
most stringent disease definition of at least five flexural skin boils, are documented in Table 3; from 
these, 10,146 criteria-diagnosed cases were extrapolated. Table 3 also documents the proportions 
within each sub-algorithm confirmed to have had 1-4 flexural boils with ‘yes’ responses to questions 
one and two only, representing a group of probable HS cases. Overall, only one validation 
questionnaire confirmed the presence of scarring with a ‘yes’ answer to question four. 
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Using the denominator of 4,364,308 research-standard patients in CPRD, the prevalence of 
physician-diagnosed and criteria-diagnosed HS cases on 30 June 2013 was 7.7 per 1,000 (95% CI 7.6, 
7.8). When the 18,417 patients with 1-4 flexural skin boils were included, the upper limit of probable 
HS prevalence was 11.9 per 1,000 (95% CI 11.8, 12.0). 
The demographic profile of physician-diagnosed HS patients is shown in Figure 2. Peak prevalence of 
15.1 per 1,000 occurred in the fifth decade of life and the mean female: male ratio across all the age 
groups was 2.9: 1. 
Incidence of physician-diagnosed cases 
The Brameld-Holman actuarial retrograde survival curve used for the backcasting correction for 
incidence rates is in Figure S1 (see Supporting Information), with the resulting correction factors 
reducing the number of new physician-diagnosed cases prior to 1994. Mean annual incidence rate 
for physician-diagnosed cases from 1996 to 2013 was 28.3 per 100,000 person-years (Table S1). Prior 
to 1995, despite the backcasting correction, annual incidence rates became progressively higher, 
ranging from 35.7 per 100,000 person-years in 1995 to 122.1 in 1988. 
Case-control 
Descriptive statistics for the occurrence of environmental factors and other medical conditions in 
cases and controls are in Table 4. Obesity (BMI > 30 kgm-2), current smoking and type 2 diabetes 
mellitus were strongly linked with physician-diagnosed cases of HS, with odds ratios (ORs) of 3.29 
(95% CI 3.14, 3.45), 3.61 (95% CI 3.44, 3.79) and 3.39 (3.09, 3.71) respectively in the univariable 
analysis (Table 4). There was a significant association between HS and Crohn’s disease but not 
ulcerative colitis. The link with Crohn’s disease was not stronger for smokers compared with non-
smokers (P=0.26 for interaction test between Crohn’s disease and never or past/current smoker). 
Associations were also found between HS and hyperlipidaemia, pilonidal sinus, acne vulgaris, 
depression and hypertension, but not with inflammatory arthritis, polycystic ovary syndrome (PCOS), 
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psoriasis, or Alzheimer’s disease (Table 4). Multivariable analysis confirmed the univariable analysis 
results in all cases (Table S2).       
 
Discussion 
Our HS prevalence figure of 0.77% is derived from a population of 4.3 million UK residents with 
research-standard medical records. Importantly, our study has identified previously undiagnosed HS 
patients using the most stringent diagnostic criteria available. We have also identified an upper limit 
of probable HS prevalence of 1.19%, if those with a history of 1-4 flexural skin boils on separate 
occasions are included. This is in the context that patients may not see their GP for every new skin 
boil, GPs may not record each skin boil, particularly if the consultation also covers other medical 
issues, and HS disease definitions vary in the number of flexural skin boils required from 2-5.5-6  
Our two prevalence figures span the 0.97% estimate for European prevalence derived from a self-
reported questionnaire study of 10,000 members of the French population which is often cited as 
the most accurate current estimate.14 In the French study, cases were identified by positive 
responses to one question within a general skin disease survey and the morphology of skin lesions 
was not assessed by healthcare professionals. 
One of the largest population-based HS investigations performed prior to our study used data from 
the Rochester Epidemiology Project (REP), which maintains a centralised electronic medical record 
database for the 144,000 people living in Olmsted County Minnesota, USA.15, 16 Identification of HS 
cases used codes including synonyms of ‘hidradenitis’, as well as the terms ‘infection, sweat gland or 
inflammation, sweat gland’. Validation by chart review identified 178 HS cases, giving a prevalence 
of 0.13%. More recently, interrogation of pooled insurance and self-pay databases covering 48 
million people in the USA using ICD-9 coding for HS gave a point prevalence of 0.10%.17 In both 
studies, identification of undiagnosed cases by considering multiple flexural skin boil presentations 
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was not attempted. Part of the explanation for the lower USA prevalence figures compared with our 
data is failure to capture undiagnosed cases. In addition, recognition and coding of HS by health care 
professionals will vary from region to region and variations in health systems may influence whether 
people with HS persevere with seeking medical attention for their condition, an issue requiring 
further investigation.     
Our finding of peak HS prevalence in women in their fourth and fifth decades of life is in agreement 
with the French self-reported questionnaire study, in which the female: male ratio was 2.7:1 and the 
mean age of patients was 43.2 years.14 Our peak prevalence finding of 1.51% in women in their fifth 
decade is lower than the 4% prevalence found by examination of a group of female healthcare 
professionals and those attending for benign skin lesions in Denmark, but the study had a relatively 
low sample size of 100, in which there were four cases.8  
Our mean annual incidence of physician-diagnosed HS cases of 28.3 per 100,000 person-years from 
1996 to 2013 is more than four times higher than the 6.0 per 100,000 person-years figure found 
using REP data for Olmsted County Minnesota.16 The difference is in keeping with the higher 
prevalence figure for physician-diagnosed cases found in our study. The more recent study of the 
USA population using pooled insurance and self-pay databases found a HS incidence of 11.4 (95% CI 
11.1 to 11.8) per 100,000 population, double the incidence of the REP-derived estimate.18 Our 
calculated incidence rates were much higher in the first few years of available CPRD data, despite 
the backcasting correction to negate any prevalent pool effect. The observation is likely explained by 
bulk computerisation of patient paper records during this period, producing an artefact in this result.  
Our case-control study is entirely consistent with other, smaller studies previously performed. A 
recent systematic review of nine relevant studies containing 6174 patients and 24,993 controls 
confirmed an association between HS and obesity (OR 3.45, 95% CI 2.20, 5.38), as well as an 
association with diabetes (OR 2.85, 95% CI 1.34, 6.08), current smoking (OR 4.34, 95% CI 2.48, 7.60) 
and past smoking (OR 6.34, 95% CI 2.41, 16.68).19 Our finding that HS is associated with Crohn’s 
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disease but not ulcerative colitis is in agreement with other studies, including a cross-sectional 
investigation of 3,267 HS patients20 and, in addition, we showed that the association between HS 
and Crohn’s disease is not modified by smoking status. The higher rates of smoking, type 2 diabetes 
mellitus, hypertension and hyperlipidaemia confirmed by our study are in keeping with the nearly 
doubled risk of cardiovascular-associated death in Danish HS patients compared with controls 
(adjusted incidence rate ratio 1.95, 95% CI 1.42, 2.67).21  
The strongest association demonstrated by our case-control study was between HS and pilonidal 
sinus, with an odds ratio of 5.61. The result is expected because both conditions are members of the 
‘follicular occlusion tetrad’ and there is ongoing debate about whether pilonidal sinus may be a 
phenotypic variant of HS. We confirmed a link between HS and depression, with an odds ratio of 
1.55, which is in keeping with a chronic, painful and socially isolating disease and in agreement with 
a study of psychiatric comorbidities in 3207 HS patients (adjusted OR for depression 1.7, 95% CI 1.3-
2.1).22 However, we did not assess the timing of disease associations in our study and so cannot 
comment further on possible causation.   
Debate continues regarding a possible link between HS and inflammatory arthritis. A syndrome 
known as PAPASH (pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis) 
has been proposed but we did not find evidence of an association between HS and inflammatory 
arthritis or psoriasis.23 Our finding of no link between HS and PCOS disagrees with a case-control 
study based on 2292 patients in the USA with at least one billing code for HS, which found an odds 
ratio of 13.7 (95% CI 4.00, 47.3).24 However, the study found a HS prevalence of only 0.08%, 
reflecting limited case-capture from billing codes, and so case ascertainment bias may have affected 
the results. We specifically checked for any link between HS and Alzheimer’s disease because of 
reports of loss of function gamma secretase gene mutations in some Han Chinese HS patients and a 
small proportion of European families with HS.25,26 Missense gamma secretase gene mutations are 
implicated in familial Alzheimer’s disease.27 We found no association between HS and Alzheimer’s 
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disease, in agreement with a recent case-control study from Denmark,28 although it is possible that 
our relatively young cohort of patients might subsequently develop dementia later in life.   
Considering our study limitations, some relevant data is missing within CPRD and it is likely that 
these will not be missing at random because cases are likely to have greater completeness due to 
their condition, increasing GP contacts and providing more opportunity for the data items to be 
recorded. Coding imperfections may affect results, mitigated by our validation of undiagnosed cases 
using the GP questionnaire. Study budget limitations, rather than statistical considerations, 
restricted the number of validation questionnaires that were sent and so a sampling error is 
possible.  
We did not validate physician-diagnosed HS cases because false positives are unlikely in the context 
that HS is a clinically diagnosed, characteristic skin disease with a low chance of being confused with 
other skin conditions. Review of medical records for patients who had received at least two ICD-9 
705.83 codes for ‘hidradenitis’ in the Massachusetts General Hospital database was previously 
conducted, in the context that the 705.83 code includes neutrophilic eccrine hidradenitis, and 
recurrent palmoplantar hidradenitis, as well as HS.29 Confirmation of HS was obtained in 89.6% of 
cases, while inclusion of the terms “hidradenitis” or “HS” in the medical record gave positive 
predictive values of 99.6% (95% CI 98.9-99.9%) and 100% (95% CI 95.8-100%) respectively for 
identification of chart-verified HS. To minimise any risk of false positives we used only the Read 
codes for ‘hidradenitis’ and ‘hidradenitis suppurativa’ in our search for physician-diagnosed cases in 
CPRD and used the specific ICD-10 code for ‘hidradenitis suppurativa’, L73.2, when searching HES 
data.    
Validation in person would have been ideal but is not possible within the ethical parameters of 
CPRD. Validation using a GP questionnaire to check for the consensus definition of five flexural skin 
boils would be prone to false negatives. This is because five skin boil consultations may not be 
recorded as separate entries in the medical record in those with a known diagnosis. For the same 
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reason, we did not analyse the performance of our algorithms in detecting physician-diagnosed 
cases. Descriptive statistics comparing controls with proxy cases and diagnosed cases support a 
conclusion that the proxy group contains mainly HS patients as well as some individuals who do not 
have HS, while the physician-diagnosed HS group is representative of a HS population. For example, 
smoking is a known HS risk factor and our physician-diagnosed group contained 51% active smokers, 
compared with 40% in the proxy group and 24% in controls.     
In conclusion, analysis of the 4.3 million UK people with research-standard medical records in CPRD 
has permitted the most comprehensive estimate of HS prevalence so far obtained, identifying 
physician-diagnosed and criteria-diagnosed cases in primary care. Prevalence of HS in the UK is 
0.77% using the most stringent validation criteria of five flexural skin boils, rising to a maximum 
possible prevalence of 1.19% if patients with a history of 1-4 flexural skin boils are included. Our 
results demonstrate that HS is a common condition, highlighting the relative lack of HS clinical trial 
evidence to date. For example, the recent HS Cochrane review included only 12 randomised 
controlled trials, involving only 615 participants, one seventh of the number of trials and participants 
included in the updated Cochrane review of vitiligo, a condition with a similar prevalence.30,31 
Availability of an accurate prevalence figure is one of the key foundations to drive further research in 
the field of HS.         
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Table 1 Description of algorithms used to identify proxy hidradenitis suppurativa cases in CPRD  
 
Sub-
algorithm 
Description 
1a ≥ 5 boils, furuncles, carbuncles or abscesses in flexural skin sites 
 
1b 1-4 boils in flexural sites & ≥ 5 boils in total 
 
1c ≥ 5 boils in unspecified skin sites 
 
2a “Multiple boils” & ≥ 1 flexural boil 
 
2b “Multiple boils”  & no flexural lesion specified 
 
3 “Drainage or Incision of boil of skin” & ≥ 5 boils in total 
 
4 Surgical excision / laser destruction of flexural skin 
 
5a ≥ 5 short courses of oral flucloxacillin / erythromycin / clarithromycin & ≥ 1 flexural 
boil, excluding eczema / skin ulcer / cellulitis 
5b ≥ 5 short courses of oral flucloxacillin / erythromycin / clarithromycin & ≥ 1 boil in 
unspecified skin site, excluding eczema / skin ulcer / cellulitis 
 
 
 
Table 2 Validation questionnaire sent to the primary care physicians of a subset of proxy HS cases 
 
Question Domain Wording Response 
1 Characteristic 
lesions 
Has your patient experienced painful, erythematous 
papules, nodules or abscesses of the skin (boils)?  
Yes/ no 
2 Flexural sites Were these lesions predominantly located in flexural 
skin sites, specifically the axillae, groins, buttocks, 
perineum and/or inframammary regions? 
Yes/ no 
3 Chronicity Has your patient experienced at least five of these 
lesions in flexural skin sites since the age of 10? 
Yes/ no 
4 Scarring Does your patient have any “rope-like” scars, atrophic 
(depressed) scars or sinus tracts in affected sites? 
Yes/ no/ 
unknown 
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Table 3 Sub-algorithm validation from completed questionnaires returned by primary care 
practitioners 
 
Sub-
algorith
m 
Questionnair
es sent 
Questionnair
es 
completed 
Proxy 
cases 
prior to 
validati
on 
Proporti
on 
validated 
with ≥ 5 
flexural 
boils 
Extrapolat
ed number 
of criteria-
diagnosed 
casesa 
Proporti
on 
validated 
with 1-4 
flexural 
boils 
Extrapolat
ed 
additional 
probable 
casesb 
1a 10 6 650 0.67 435 0 0 
1b 10 6 1908 0.33 629 0.17 325 
1c 10 7 3120 0.57 1778 0.29 905 
2a 10 3 2083 0.33 687 0.34 708 
2b 59 38 27,492 0.13 3573 0.29 7973 
3 0 0 0 0 0 0 0 
4 10 5 594 0 0 0.20 118 
5a 14 10 7050 0.10 705 0.60 4229 
5b 53 32 25,993 0.09 2339 0.16 4159 
Total 176 107 68,890  10,146  18,417 
 
 
(a) ‘Criteria-diagnosed cases’ are defined as those confirmed by their primary care physician to 
have a history of at least five flexural skin boils. 
‘Additional probable cases’ are defined as those confirmed by their primary care physician to have a 
history of between one and four flexural skin boils. 
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Table 4 Case-control study univariable analysis 
 
 Control n  
(%) 
Proxy case n 
(%) 
Physician-
diagnosed 
case n (%) 
Proxy cases Physician-diagnosed cases of 
hidradenitis suppurativa 
    OR (95% CI) P-value OR (95% CI) P-value 
Obesity (BMI>30) 19862 (21.2) 29916 (42.8) 11145 (46.4) 2.77 (2.70, 2.85) <0.001 3.29 (3.14, 3.45) <0.001 
Type 2 diabetes mellitus 17689 (4.8) 30845 (9.0) 2167 (9.0) 3.32 (3.18, 3.47)  <0.001 3.39 (3.09, 3.71) <0.001 
Smoking status        
     Never 48431 (51.6) 28751 (41.2) 7828 (32.6) 1  1  
     Past  12671 (13.5) 10523 (15.1) 3260 (13.6) 1.44 (1.39, 1.49) <0.001 1.93 (1.81, 2.05) <0.001 
     Current 22712 (24.2) 27748 (39.7) 12347 (51.4) 2.18 (2.13, 2.24) <0.001 3.61 (3.44, 3.79) <0.001 
Crohn’s disease 708 (0.2) 310 (0.4) 122 (0.5) 2.21 (1.81, 2.69) <0.001 2.65 (1.89, 3.72) <0.001 
Ulcerative colitis 521 (0.1) 78 (0.1) 42 (0.2) 0.82 (0.61, 1.11) 0.2 1.24 (0.79, 1.94) 0.36 
Pilonidal sinus 293 (0.3) 887 (1.3) 444 (1.9) 4.21 (3.62, 4.89) <0.001 5.61 (4.41, 7.12) <0.001 
Acne vulgaris 5828 (6.2) 7858 (11.3) 2885 (12.0) 2.17 (2.09, 2.27) <0.001 1.77 (1.66, 1.88) <0.001 
Depression 56050 (15.3) 16968 (24.3) 6138 (26.3) 1.65 (1.60, 1.69) <0.001 1.69 (1.62, 1.77) <0.001 
Hyperlipidaemia 10871 (3.0) 3344 (4.8) 791 (3.3) 1.59 (1.50, 1.69) <0.001 1.79 (1.59, 2.02) <0.001 
Hypertension 33457 (9.1) 8596 (12.3) 1882 (7.8) 1.40 (1.35, 1.45) <0.001 1.42 (1.32, 1.53) <0.001 
Inflammatory arthritis 3000 (0.8) 634 (0.9) 201 (0.8) 1.06 (0.94, 1.18) 0.35 1.06 (0.87, 1.30) 0.54 
PCOS 377 (0.4) 252 (0.4) 181 (0.8) 1.12 (0.94, 1.34) 0.22 1.19 (0.96, 1.49) 0.11 
Psoriasis 3444 (0.9) 671 (1.0) 247 (1.0) 1.03 (0.92, 1.15) 0.62 1.09 (0.91, 1.31) 0.33 
Alzheimer’s disease 529 (0.1) 87 (0.1) 16 (0.01) 0.95 (0.71, 1.27) 0.71 1.60 (0.73, 3.53) 0.24 
 
Based on 93,869 control individuals, 69,842 proxy cases including criteria-diagnosed hidradenitis suppurativa (HS) cases and those who did not meet the 
validation criteria, and 24,027 physician-diagnosed cases of HS. Smoking status was missing from a total of 10,055 records, including 2,820 proxy cases and 
592 physician-diagnosed cases. PCOS = polycystic ovary syndrome. 
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Figure titles and legends 
 
Figure 1: Algorithm hierarchy used to capture unrecognised cases of hidradenitis suppurativa. 
Legend: Schematic representation of sub-algorithms used to detect unrecognised hidradenitis 
suppurativa with differing degrees of stringency. 
 
Figure 2: Demographics of physician-diagnosed hidradenitis suppurativa cases. 
Legend: Line graph of the prevalence rate of physician-diagnosed hidradenitis suppurativa in UK 
males, females and in total, subdivided by decade of age. Superimposed is a histogram of the 
female: male ratio for each decade of age.  
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Figure 1: Algorithm hierarchy used to capture unrecognised cases of hidradenitis suppurativa 
 
 
 
 
Legend: Schematic representation of sub-algorithms used to detect unrecognised hidradenitis 
suppurativa with differing degrees of stringency. 
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Figure 2: Demographics of physician-diagnosed hidradenitis suppurativa cases. 
 
 
 
Legend: Line graph of the prevalence rate of physician-diagnosed hidradenitis suppurativa in UK 
males, females and in total, subdivided by decade of age. Superimposed is a histogram of the 
female: male ratio for each decade of age. 
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